Huawei Technologies’ founder and CEO Ren Zhengfei has dismissed U.S. warnings about the company’s Ascend AI chips, suggesting the United States is overstating their technological capabilities. In a statement published by China’s state-run People’s Daily on Tuesday, Ren clarified that Huawei relies on group computing to boost performance rather than depending solely on individual chip power.
The comments come in response to recent guidance from the U.S. Commerce Department, which warned that using Huawei’s Ascend series may violate American export control laws. These chips, developed by the Shenzhen-based tech giant, are considered Huawei’s most advanced semiconductors and have raised concerns in Washington over potential national security risks.
Ren’s remarks appear aimed at downplaying the chips’ standalone processing power, potentially softening international scrutiny. “Our strength lies in cluster computing, not in single-chip dominance,” he reportedly said, highlighting Huawei’s focus on distributed computing systems.
The U.S. government has been intensifying pressure on Huawei for years, citing its close ties to the Chinese government. The Ascend series, used in AI applications and data centers, is seen as a milestone for China’s domestic semiconductor ambitions amid ongoing restrictions on access to advanced chipmaking tools from U.S. suppliers.
Huawei’s rebuttal suggests a strategic effort to reduce the perception of technological threat posed by the Ascend chips, possibly to ease regulatory tension. Despite export restrictions and sanctions, Huawei continues to push forward with innovation in AI and chip design, while carefully navigating international compliance concerns.
This latest development underscores the ongoing tech standoff between China and the U.S., particularly in AI and semiconductor sectors, as both nations vie for leadership in next-generation computing technologies.


Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook
US Quantum Stocks Surge After $2 Billion Government Investment
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements
SQM Q1 Profit More Than Doubles as Lithium Prices Surge
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 



